Kardigan, a San Francisco, CA- and Princeton, NJ-based health company modernizing cardiovascular (CV) drug development, acquired Prolaio, a Chicago, IL-based clinical intelligence company advancing cardiology research and care with real-world patient data and insights.
The amount of the deal was not disclosed.
With the acquisition, Kardigan will gain access to Prolaio’s CV data collection and analytics platform.
Co-founded by Tassos Gianakakos, and Jay Edelberg, M.D., Ph.D., Prolaio provides a platform that includes a tech-enabled clinical trial enrichment capability, which translates high-density data into insights specifically designed for CV conditions. It enables researchers to optimize clinical study design, increase statistical power, reduce overhead, and enhance confidence with better data throughout the study. In addition to these clinical research capabilities, the company improves how patients access individualized care in the future, transforming CV care delivery as well as patient engagement and satisfaction.
It will continue to function independently as a CV-focused technology company providing real-world driven insights and services to both its biopharma and CV provider partners.
Kardigan is a patient-driven heart health company leveraging cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, it is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve.
FinSMEs